Pacira BioSciences is fighting a proxy battle over $726.4 million in 2025 revenue — and the argument being made is essentially that a 31% stock gain since the 5×30 strategy launched is proof enough that activist pressure is noise, not signal. That framing matters, because DOMA Perpetual Capital Management is trying to replace three board nominees at a June 9 annual meeting, and the incumbent board’s entire defense rests on operational momentum rather than any structural concession to shareholder concerns. That is a risky posture when activists have a platform.
The substance of Pacira’s case is stronger than most proxy defenses. Record gross margins of 81.2% on a non-GAAP basis, EXPAREL volume growth accelerating from 3.6% in 2024 to 8% in the back half of 2025, a Johnson & Johnson MedTech commercial partnership that tripled U.S. physician reach, and an EXPAREL patent settlement locking out generics until 2030 with a capped transition through 2039 — that is a coherent picture of a company that has stabilized. The gene therapy asset PCRX-201 targeting osteoarthritis and the in-licensed ropivacaine candidate PCRX-2002 extend the story into the pipeline, which is where Pacira had historically been weakest. Three Phase 2 data readouts expected before year-end will test whether the pipeline narrative survives contact with clinical reality.
What DOMA’s challenge actually exposes is a valuation problem management cannot talk its way out of. A 31% stock rise sounds impressive until you note that PCRX was sharply depressed when the 5×30 strategy launched, and the EXPAREL settlement, while favorable structurally, still defines the ceiling on the company’s core franchise through 2039. Dependence on one liposomal bupivacaine product for the bulk of commercial revenue is precisely the vulnerability DOMA is pressing. The board’s answer — five pipeline programs, five partnerships, and patient volume toward three million annually by 2030 — is a strategy, not yet a result. Investors voting on June 9 are being asked to price ambition on the evidence of one good year.
The single number to watch after the annual meeting is EXPAREL volume growth in Q3 2026. Management has explicitly forecast that volume and sales growth will converge in the second half of this year — a claim that strips away pricing and mix effects. If volume growth stalls below 8%, the proxy fight will have been the opening act, not the main event.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
